An overview of VTE
This guide provides an overview of the signs and symptoms, risk factors, and complications of VTE.
- VTE patient information leaflet - Helping to treat deep vein thrombosis and pulmonary embolism, and helping prevent recurrence
- Anticoagulant alert card – Providing helpful reminders for patients and vital information for healthcare professionals that treat them
This guide provides an overview of the dosing regimens, and clinical pharmacology of NOACs.
This guide provides an overview of the results from key clinical trials of NOACs in VTE.
ELIQUIS in VTE
To support you with initiating ELIQUIS (apixaban) in your patients with VTE you can use our DVT / PE Prescriber Checklist, available here.
Click here to view ELIQUIS (apixaban) prescribing and adverse event reporting information.
ACCP = American College of Chest Physicians AF = Atrial Fibrillation BD = Twice Daily CI = Confidence Interval CPRD = Clinical Practice Research Datalink CrCl = Creatinine Clearance CTEPH Chronic Thromboembolic Pulmonary Hypertension DVT = Deep Vein Thrombosis ESC = European Society of Cardiology HCP = Health Care Professional INR = International Normalised Ratio LMWH = Low Molecular Weight Heparin NHS = National Health Service NICE = National Institute for Health and Care Excellence NOAC = Non-vitamin K antagonist Oral Anticoagulant OAC = Oral Anticoagulant OD = Once Daily PE = Pulmonary Embolism PTS = Post-Thrombotic Syndrome SIGN = Scottish Intercollegiate Guidelines Network SMC = Scottish Medicines Consortium VKA = Vitamin K Antagonist VTE = Venous Thromboembolism
Job code: 432UK1900506-01
Date of preparation: September 2019